Patent data mining: A tool for accelerating HIV vaccine innovation

Vaccine

Volumn 29, Issue 24, 2011, Pages 4086-4093

  Clark, K ^a   Cavicchi, J ^b   Jensen, K ^a   Fitzgerald, R ^b   Bennett, A ^a   Kowalski, S P ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Franklin Pierce Law Center   (United States)

Author keywords

HIV; Intellectual property; Patent; Patent landscape; Vaccines

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ARTICLE; CLINICAL DECISION MAKING; COMMERCIAL PHENOMENA; DATA MINING; DRUG EFFICACY; HEALTH CARE ACCESS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LANDSCAPE; LICENSING; NONHUMAN; ORGANIZATION AND MANAGEMENT; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; SCIENTIFIC LITERATURE;

ADENOVIRIDAE; AIDS VACCINES; DATA MINING; DATABASES, FACTUAL; GENETIC VECTORS; HIV INFECTIONS; HUMANS; PATENTS AS TOPIC; VACCINES, DNA;

EID: 79956106358     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.03.052     Document Type: Article

References (35)

1. Knowles L., Bubela T. Challenges for intellectual property management of HIV vaccine-related research and development (The Global Context, part 1). Health Law Journal 2008, 16:55-95.
2. Murray F., Stern S. Do formal intellectual property rights hinder the free flow of scientific knowledge? An empirical test of the anti-commons hypothesis. Journal of Economic Behavior and Organization 2007, 63(4):648-687.
3. Heller M.A., Eisenberg R. Can patents deter innovation? The anticommons in biomedical research. Science 1998, 280(5364):698-701.
4. Holman C. Clearing a path through the patent thicket. Cell 2006, 125(4):33-629.
5. Intellectual property rights: summary report and recommendations of an international meeting, New York, International AIDS Vaccine Initiative; 1996 [cited 2009 October 19].
6. " Intellectual Property Rights and Vaccines in Developing Countries" meeting report 19-20 April 2004. http://www.who.int/vaccines-documents/DocsPDF05/Dip-789-screen.pdf.
7. Aide P., Aponte J.J., Renom M., Nhampossa T., Sacarlal J., Mandomando I., et al. Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial. PLoS One 2010, 5(November (11)):e13838.
8. Inglis S., Shaw A., Koenig S. Chapter 11: HPV vaccines: commercial research & development. Vaccine 2006, 24(August (Suppl. 3)). S3/99-105 [Epub 2006 June 23].
9. Padmanabhan S., Amin T., Sampat B., Cook-Deegan R., Chandrasekharan S. Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in India. Nature Biotechnology 2010 Jul, 28(7):671-678.
10. Mahoney R. Public private partnership in the development of the hepatitis B vaccine in Korea: implications for developing countries. Science Technology Society 2005, 10:129.
11. Mahoney R. DNA Hepatitis B Vaccine: International Vaccine Institute, Korea. Intellectual property management in health and agricultural innovation: a handbook of best practices 2007, 131-144. US ThomsonShore Inc, Available online at www.ipHandbook.org. A. Krattiger, R.T. Mahoney, L. Nelsen, J.A. Thomson, A.B. Bennett, K. Satyanarayana, G.D. Graff, C. Fernandez, S.P. Kowalski (Eds.).
12. Bergman K., Graff G.D. The global stem cell patent landscape: implications for efficient technology transfer and commercial development. Nature Biotechnology 2007, 25(4):24-419.
13. Bahadur G., Morrison M. Patenting human pluripotent cells: balancing commercial, academic and ethical interests. Human Reproduction 2010, 25(January (1)):14-21. [Epub 2009 November 7].
14. Jensen K., Murray F. Intellectual property. Enhanced: intellectual property landscape of the human genome. Science 2005, 310(October (5746)):239-240.
15. The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan. Global HIV/AIDS Vaccine Enterprise. PLoS Medicine 2005, 2(2):e25.
16. Fuller M. Twenty years of transgenic animals: are some inventions SO important as to NOT be entitled to full patent protection?. World Patent Information 2008, 30(2):139-143.
17. Krattiger A., Kowalski S., Eiss R., Taubman A. Intellectual property management strategies to accelerate the development and access of vaccines and diagnostics: case studies on pandemic influenza, malaria and SARS. Innovation Strategy Today 2006, 2(2):67-122.
18. Krattiger A., Kowalski S. Facilitating assembly of and access to intellectual property: focus on patent pools and a review of other mechanisms. Intellectual property management in health and agricultural innovation: a handbook of best practices 2007, 131-144. US ThomsonShore Inc, Available online at www.ipHandbook.org. A. Krattiger, R.T. Mahoney, L. Nelsen, J.A. Thomson, A.B. Bennett, K. Satyanarayana, G.D. Graff, C. Fernandez, S.P. Kowalski (Eds.).
19. IAVI clinical trials database. [accessed 25.08.09]. http://www.iavireport.org/trials-db/Pages/default.aspx.
20. A (prime) boost for HIV vaccine research?. Lancet 2009, 374(9696):1119.
21. Burton D.R., Desrosiers R.C., Doms R.W., Feinberg M.B., Gallo R.C., Hahn B., et al. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science 2004, 303:316.
22. Blanchard A. Understanding and customizing stopword lists for enhanced patent mapping. World Patent Information 2007, 29(4):16-308.
23. Attaran A. How do patents and economic policies affect access to essential medicines in developing countries?. Health Affairs 2004, 23(3):155-166.
24. Barouch D.H., Korber B. HIV-1 vaccine development after STEP. Annual Reviews in Medicine 2010, 61:153-167.
25. Mahoney R.T., Krattiger A., Clemens J.D., Curtiss R. The introduction of new vaccines into developing countries IV: Global Access Strategies. Vaccine 2007, 25:4003-4011.
26. Jadhav S.S., Gautam M., Gairola S. Emerging markets & emerging needs: developing countries vaccine manufacturers' perspective & its current status. Biologicals 2009, 37(June (3)):165-168.
27. Wagner J.A. Open-minded to open innovation and precompetitive collaboration. Clinical Pharmacology and Therapeutics 2010, 87(May (5)):511-515.
28. Pilat D., De Backer K., Basri E., Box S., Cervantes M. The development of global innovation networks and the transfer of knowledge. Innovation and growth: chasing a moving frontier, OECD 2009, 85-105. The World Bank. OECD Publishing. C.A. Primo-Braga, P.C. Padoan, V. Chandra, D. Eröcal (Eds.).
29. Widdus R. Public private partnerships: an overview. Transactions of the Royal Society of Tropical Medicine and Hygiene 2005, 99(Suppl. 1):S1-S8.
30. International AIDS Vaccine Initiative Product Development Public-Private Partnerships (PDPs): A Driving Force for New Vaccines and Drugs 2006, Available online: http://www.iavi.org/publications-resources/pages/PublicationDetail.aspx?pubID=fcc09677-ae07-436c-b194-0fc08a9cdb64.
31. Butler D. Neglected diseases fund touted. Nature 2010, 465:277.
32. Wagner J.A., Prince M., Wright E.C., Ennis M.M., Kochan J., Nunez D.J., et al. The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration. Clinical Pharmacology and Therapeutics 2010, 87(May (5)):539-542.
33. WIPO, World Intellectual Property Indicators, 2010 Edition, available at: http://www.wipo.int/ipstats/en/statistics/patents.
34. Kowalski S.P. Freedom to operate: the preparations. Intellectual property management in health and agricultural innovation: a handbook of best practices 2007, MIHR/PIPRA, Oxford, U.K./Davis, U.S.A., Available online at www.ipHandbook.org. A. Krattiger, R.T. Mahoney, L. Nelsen (Eds.).
35. McCarthy J.T., Schechter R.E., Franklyn D.J. McCarthy's Desk Encyclopedia of Intellectual Property 2004, The Bureau of National Affairs, Inc., Washington, DC.